# FDA 483 - Geri-Care Pharmaceuticals Corp. - May 05, 2025

Source: https://www.keypedia.com/records/483/geri-care-pharmaceuticals-corp/aa1c2161-bd6a-44d7-a584-f3a432a7004e

> FDA 483 for Geri-Care Pharmaceuticals Corp. on May 05, 2025. Product: drugs. Access full analysis and detailed observations.

---

## Details

- Record Type: 483
- Company Name: Geri-Care Pharmaceuticals Corp.
- Inspection Date: 2025-05-05
- Product Type: drugs
- Office Name: New Jersey District Office
- Summary: Geri-Care Pharmaceuticals Corp., an OTC drug repackager and distributor in Lakewood, NJ, was cited for significant quality control deficiencies during an FDA inspection. The firm failed to implement adequate supplier qualification, lacked a written stability program, and did not thoroughly investigate deviations or customer complaints. Additionally, the company did not perform annual visual inspections of reserve drug product samples.

## Related Officers

- [Alisha B. Patel](https://www.keypedia.com/people/alisha-b-patel/3c106dac-0e0d-41f2-9f7a-69982d4e6579)
- [Consumer Safety Officer - Dedicated Foreign Drug Cadre](https://www.keypedia.com/people/tamil-arasu/94efc491-7d9f-4221-a1ee-69a925acb1c3)

Company: https://www.keypedia.com/companies/geri-care-pharmaceuticals-corp/d8db3389-a5a8-420c-98d3-18233610e854

Office: https://www.keypedia.com/offices/new-jersey-district-office/6ff5e2e9-5cff-44c7-af24-5a55329a8248